Current treatments for schizophrenia are efficient for about only half of patients. In addition, they involve severe neurological and metabolic side effects and can lead to reduced patient cooperation and compliance. New long-acting injectable therapies can increase compliance for individuals with schizophrenia during incarceration and as they transition to community care settings. In addition, new views of the biology of schizophrenia are converging with novel drugs targeting brain mechanisms that might treat symptoms in different ways. This program will review brain science and current and future treatment options to reduce exacerbation of illness and recidivism. 

Educational objectives
• Describe current treatment strategies for patients with schizophrenia
• Discuss the future direction of schizophrenia treatment
• Explain the impact of targeted pharmacotherapy on recidivism and integration into community treatment

Made possible by an educational grant from Alkermes.